MX390288B - Formulación y método para el tratamiento de la alopecia androgénica. - Google Patents

Formulación y método para el tratamiento de la alopecia androgénica.

Info

Publication number
MX390288B
MX390288B MX2018001546A MX2018001546A MX390288B MX 390288 B MX390288 B MX 390288B MX 2018001546 A MX2018001546 A MX 2018001546A MX 2018001546 A MX2018001546 A MX 2018001546A MX 390288 B MX390288 B MX 390288B
Authority
MX
Mexico
Prior art keywords
weight
formulation
treatment
finasteride
minoxidil
Prior art date
Application number
MX2018001546A
Other languages
English (en)
Other versions
MX2018001546A (es
Inventor
Sergio Nacht
Original Assignee
Centro Int De Cosmiatria S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Int De Cosmiatria S A P I De C V filed Critical Centro Int De Cosmiatria S A P I De C V
Priority to MX2018001546A priority Critical patent/MX390288B/es
Priority to PCT/MX2019/000008 priority patent/WO2019156545A1/es
Priority to US16/968,018 priority patent/US12029811B2/en
Priority to EP19750425.1A priority patent/EP3750542A4/en
Publication of MX2018001546A publication Critical patent/MX2018001546A/es
Publication of MX390288B publication Critical patent/MX390288B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una formulación tópica para usarse en el tratamiento de calvicie androgénica o androgenética tanto en hombres como mujeres con efectos secundarios reducidos, especialmente con menos efectos colaterales en la población femenina. La formulación tópica comprendiendo desde 0.01% hasta 10% en peso de Finasteride y una concentración desde 1% hasta 5% en peso de Minoxidil de forma libre o en un polímero poroso inerte. La combinación del Finasteride y el Minoxidil proporcionando un efecto sinérgico en contra de la calvicie. La formulación además comprende retinol en un 0.15% en peso y estando adaptada para ser administrada en el cuero cabelludo del sujeto en necesidad del mismo.
MX2018001546A 2018-02-06 2018-02-06 Formulación y método para el tratamiento de la alopecia androgénica. MX390288B (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2018001546A MX390288B (es) 2018-02-06 2018-02-06 Formulación y método para el tratamiento de la alopecia androgénica.
PCT/MX2019/000008 WO2019156545A1 (es) 2018-02-06 2019-01-31 Formulación y método para el tratamiento de la alopecia androgénica
US16/968,018 US12029811B2 (en) 2018-02-06 2019-01-31 Formulation and method for the treatment of androgenic alopecia
EP19750425.1A EP3750542A4 (en) 2018-02-06 2019-01-31 FORMULATION AND METHOD FOR THE TREATMENT OF ANDROGENIC ALOPECIA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018001546A MX390288B (es) 2018-02-06 2018-02-06 Formulación y método para el tratamiento de la alopecia androgénica.

Publications (2)

Publication Number Publication Date
MX2018001546A MX2018001546A (es) 2019-08-07
MX390288B true MX390288B (es) 2025-03-20

Family

ID=67549019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001546A MX390288B (es) 2018-02-06 2018-02-06 Formulación y método para el tratamiento de la alopecia androgénica.

Country Status (4)

Country Link
US (1) US12029811B2 (es)
EP (1) EP3750542A4 (es)
MX (1) MX390288B (es)
WO (1) WO2019156545A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118831088B (zh) * 2023-09-06 2025-04-29 北京辰光医药科技有限公司 治疗脱发的药物制剂及其制备方法与用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201436B (it) 1985-07-19 1989-02-02 Vincenzo Zappia Formulazioni topiche a lento rilascio
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
JP3004718B2 (ja) * 1990-08-10 2000-01-31 ファルマシア・アンド・アップジョン・カンパニー カリウムチャネルオープナーおよび５α―レダクターゼ抑制剤を用いる育毛刺激
CA2248496A1 (en) * 1997-10-04 1999-04-04 Unilever Plc Hair care compositions containing phytantriol
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
EP1154783A4 (en) * 1999-07-06 2005-01-19 Raziel Lurie RELAXIN-CONTAINING MEDICAMENTS AND ITS USE
DE10233740A1 (de) * 2002-07-24 2004-02-05 Basf Ag Retinoid-haltige Zubereitungen
GB0301577D0 (en) 2003-01-23 2003-02-26 Edko Pazarlama Tanitim Ltd Sti Topical pharmaceutical and/or cosmetic dispense systems
WO2009101497A2 (en) 2008-02-11 2009-08-20 Glenmark Pharmaceuticals Limited Topical pharmaceutical combination comprising minoxidil and aminexil
PL2344198T3 (pl) 2008-09-27 2021-05-31 Jina Pharmaceuticals Inc. Preparaty farmaceutyczne na bazie lipidów do stosowania miejscowego
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
PT2702982T (pt) * 2011-04-25 2017-03-17 Park Jun-Hyoung Composição para aplicação tópica para a prevenção da perda de cabelo e estimulação do crescimento capilar
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
WO2014122436A1 (en) 2013-02-07 2014-08-14 Cipla House Topical pharmaceutical compositions comprising minoxidil
WO2014184173A1 (en) * 2013-05-14 2014-11-20 Montero Gida Sanayi Ve Ticaret A.S. Hair care formulations
CN105106028B (zh) * 2015-08-28 2018-06-19 深圳市维琪医药研发有限公司 一种用于毛发生长的多肽组合物

Also Published As

Publication number Publication date
EP3750542A1 (en) 2020-12-16
MX2018001546A (es) 2019-08-07
WO2019156545A1 (es) 2019-08-15
EP3750542A4 (en) 2022-01-26
US20210106519A1 (en) 2021-04-15
US12029811B2 (en) 2024-07-09

Similar Documents

Publication Publication Date Title
PH12016502254A1 (en) Keratin treatment formulations and methods
MX2017014683A (es) Tratamiento para el rebrote del cabello y estimulante del crecimiento.
PH12018502634A1 (en) Topical compositions of apremilast
JOP20210170A1 (ar) طرق وتركيبات لعلاج اضطرابات الجلد والشعر
NZ590796A (en) Film-forming liquid formulations for drug release to hair and scalp
MX370958B (es) Uso de alquilamidotiazoles en preparaciones cosméticas o dermatológicas para la profilaxis y el tratamiento de piel sensible.
MX2021008089A (es) Composiciones y metodos para modular el crecimiento del cabello.
MX2018012704A (es) Metodo para tratar un trastorno del cabello con n-hidroxipiridinonas.
MX2021010546A (es) Composiciones y metodos para tratamiento de la piel.
CL2019000375A1 (es) Métodos y composiciones para reducir el encanecimiento del cabello
MX2018013860A (es) Composiciones cosmeticas para reparacion cutanea.
MX390288B (es) Formulación y método para el tratamiento de la alopecia androgénica.
MX2022002646A (es) Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica.
SI3057664T1 (en) Use of a composition for the pigmentation of hair and hairs
MX2018000538A (es) Composicion antimicrobiana.
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
MX394067B (es) Composicion para la prevencion y el tratamiento de los trastornos del crecimiento del cabello
MX2019008782A (es) Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.
NZ746011A (en) Glycoalkaloid combinations and various uses thereof
MX2020005682A (es) Extracto de helichrysum gymnocephalum para el tratamiento y/o la prevencion de dermatosis inflamatorias.
BR112019001799A2 (pt) composições para cuidados pessoais, processo para preparar uma composição e método não terapêutico para reduzir ou prevenir inflamação
CL2022000315A1 (es) Composición cosmética tópica, uso de la composición y tónico para aplicación facial
MX2021001090A (es) Extracto de lespedeza capitata para su uso en el campo del cuidado del cabello.
MX2022007109A (es) Composiciones para el cuidado personal y metodos para estas.
CO2018002197A2 (es) Composición tópica con actividad estimulante del folículo piloso